Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Tazemetostat

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44351   clinical trials with a EudraCT protocol, of which   7378   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    14 result(s) found for: Tazemetostat. Displaying page 1 of 1.
    EudraCT Number: 2012-004083-21 Sponsor Protocol Number: E7438-G000-101 Start Date*: 2015-02-02
    Sponsor Name:Epizyme, Inc.
    Full Title: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas
    Medical condition: Relapsed or refractory Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Advanced solid tumor
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-002469-41 Sponsor Protocol Number: EZH-202 Start Date*: 2016-04-18
    Sponsor Name:Epizyme, Inc.
    Full Title: A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
    Medical condition: Cohort 1: Rhabdoid tumors (malignant rhabdoid tumors, rhabdoid tumors of the kidney, atypical teratoid rhabdoid tumors, and selected tumors Cohort 2: Relapsed/refractory synovial sarcoma with SS18...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007284 Carcinoma LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10064886 Renal medullary carcinoma LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073134 Extraskeletal myxoid chondrosarcoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026667 Malignant peripheral nerve sheath tumor LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073335 Rhabdoid tumor LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042863 Synovial sarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015100 Epithelioid sarcomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) BE (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-001499-31 Sponsor Protocol Number: Epi-RCHOP Start Date*: 2016-08-09
    Sponsor Name:LYSARC
    Full Title: A Phase Ib-II Study of tazemetostat (EPZ-6438) in newly diagnosed Diffuse Large B Cell Lymphoma (DLBCL) patients with poor prognosis treated by R-CHOP
    Medical condition: newly diagnosed Diffuse Large B Cell Lymphoma (DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004851 10012819 Diffuse large B-cell lymphomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-003649-14 Sponsor Protocol Number: EZH-1101 Start Date*: 2020-09-07
    Sponsor Name:Epizyme, Inc.
    Full Title: A PHASE 1B/2 OPEN-LABEL STUDY EVALUATING TAZEMETOSTAT IN COMBINATION WITH ENZALUTAMIDE OR ABIRATERONE/PREDNISONE IN CHEMOTHERAPY NAIVE SUBJECTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER
    Medical condition: Metastatic Castration Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001139-10 Sponsor Protocol Number: EZH-203 Start Date*: 2016-06-27
    Sponsor Name:Epizyme, Inc.
    Full Title: A Phase 2, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with Relapsed or Refractory BAP1 deficientMalignant Mesothelioma
    Medical condition: Part 1 – Subjects with relapsed or refractory malignant mesothelioma regardless of BAP1 status Part 2 – Subjects with relapsed or refractory BAP1-deficient malignant mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027414 Mesotheliomas malignant and unspecified HLT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027407 Mesothelioma malignant PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027406 Mesothelioma PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027408 Mesothelioma malignant advanced LLT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062474 Mesothelioma malignant localized LLT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027411 Mesothelioma malignant recurrent PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027412 Mesotheliomas HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-006398-41 Sponsor Protocol Number: E7438-M081-501 Start Date*: 2022-01-27
    Sponsor Name:Eisai Co., Ltd.
    Full Title: A Post-marketing Observational Study of Tazemetostat on Safety in Patients With Relapsed or Refractory Follicular Lymphoma With EZH2 Gene Mutation in Japan
    Medical condition: Lymphoma, Follicular
    Disease: Version SOC Term Classification Code Term Level
    24.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10085128 Follicular lymphoma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2019-003648-55 Sponsor Protocol Number: EZH-301 Start Date*: 2020-08-17
    Sponsor Name:Epizyme, Inc.
    Full Title: A Phase 1b/3 Global, Randomized, Double-blind, Placebo-Controlled Trial of Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma
    Medical condition: Phase 1b: Have histologically confirmed Soft tissue sarcoma (STS). Phase 3: Morphology and immunophenotypic panel consistent with epithelioid sarcoma (eg, CD34, epithelial membrane antigen [EMA], ...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015100 Epithelioid sarcomas HLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075333 Soft tissue sarcoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) BE (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003333-42 Sponsor Protocol Number: EZH-302 Start Date*: 2020-11-09
    Sponsor Name:Epizyme, Inc.
    Full Title: A Phase 1b/3 double-blind, randomized, active-controlled, 3-stage, biomarker adaptive study of tazemetostat or placebo in combination with lenalidomide plus rituximab in subjects with relapsed/refr...
    Medical condition: Relapsed/refractory follicular lymphoma
    Disease: Version SOC Term Classification Code Term Level
    24.0 10016903 - Follicle centre lymphomas, follicular grade I, II, III 10016903 Follicle centre lymphomas, follicular grade I, II, III HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) FR (Trial now transitioned) BE (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-002468-18 Sponsor Protocol Number: EZH-102 Start Date*: 2016-02-19
    Sponsor Name:Epizyme, Inc.
    Full Title: A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects with Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
    Medical condition: Atypical teratoid rhabdoid tumor (ATRT), Malignant rhabdoid tumor (MRT), Rhabdoid tumor of kidney (RTK), selected tumors with rhabdoid features. Epithelioid sarcoma, Epithelioid malignant peripher...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10064886 Renal medullary carcinoma LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065870 Atypical teratoid/rhabdoid tumor of CNS LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073134 Extraskeletal myxoid chondrosarcoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073335 Rhabdoid tumor LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074121 Rhabdoid tumor of the kidney LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042863 Synovial sarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015100 Epithelioid sarcomas HLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DK (Completed) DE (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-005167-51 Sponsor Protocol Number: CA057-003 Start Date*: 2022-08-24
    Sponsor Name:Celgene Corporation
    Full Title: An Exploratory Phase 1b/2a Multicenter, Open-Label, Novel-Novel Combination Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of CC-92480 (BMS-986348) in Nove...
    Medical condition: Relapsed or Refractory Multiple Myeloma (RRMM)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10067095 Multiple myeloma progression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-004984-35 Sponsor Protocol Number: EZH-501 Start Date*: 2016-08-03
    Sponsor Name:Epizyme, Inc.
    Full Title: Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study
    Medical condition: Subjects will receive tazemetostat as dictated in their antecedent study.
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027414 Mesotheliomas malignant and unspecified HLT
    19.1 100000004850 10027404 Mesomelia LLT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007284 Carcinoma LLT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027406 Mesothelioma PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027408 Mesothelioma malignant advanced LLT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026667 Malignant peripheral nerve sheath tumor LLT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073335 Rhabdoid tumor LLT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042863 Synovial sarcoma PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10064886 Renal medullary carcinoma LLT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073134 Extraskeletal myxoid chondrosarcoma PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062474 Mesothelioma malignant localized LLT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074121 Rhabdoid tumor of the kidney LLT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027411 Mesothelioma malignant recurrent PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015100 Epithelioid sarcomas HLT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027412 Mesotheliomas HLGT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) PL (Trial now transitioned) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003303-35 Sponsor Protocol Number: IB2019-04 Start Date*: 2021-04-08
    Sponsor Name:Institut Bergonié
    Full Title: Combining epigenetic and immune therapy to beat cancer
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033606 Pancreatic cancer non-resectable LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033605 Pancreatic cancer metastatic LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065147 Malignant solid tumor LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039494 Sarcoma NOS LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-001843-29 Sponsor Protocol Number: TASTER2018 Start Date*: 2019-05-28
    Sponsor Name:NHS Greater Glasgow and Clyde [...]
    1. NHS Greater Glasgow and Clyde
    2. University of Glasgow
    Full Title: TASTER- TArgeting STEm cell Resistance An umbrella adaptive randomised multi–arm screening phase II trial for patients with 2nd/3rd generation TKI resistant chronic myeloid leukaemia
    Medical condition: Chronic myeloid leukaemia
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009013 Chronic myeloid leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2017-001267-21 Sponsor Protocol Number: BO39610 Start Date*: 2018-01-25
    Sponsor Name:F. Hoffman-La Roche Ltd.
    Full Title: A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH METASTATIC NONSMALL CEL...
    Medical condition: Metastatic non-small cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) FR (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jul 20 14:19:56 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA